An Introduction to Diederik van der Reijt: CEO & Founder of Celljevity

As an accomplished entrepreneur and visionary leader, Diederik van der Reijt has built an extraordinary career at the intersection of finance, biotechnology, and regenerative medicine. With a proven track record of fostering innovation and building transformative businesses, Diederik’s leadership has set a new standard for healthcare innovation. Today, he serves as the CEO and Founder of Celljevity, a pioneering company in regenerative medicine focused on addressing degenerative diseases and extending human healthspan through groundbreaking technologies.

Before embarking on his journey in healthcare, Diederik demonstrated his business acumen across various sectors. He led global teams, navigated complex financial systems, and developed a deep understanding of building sustainable, high-growth enterprises. Now, he applies these skills to revolutionize how we understand and treat diseases, steering Celljevity into the future of medicine.

A Journey Built on Vision and Drive

Diederik’s professional journey began in the high-pressure environment of the Amsterdam Options Exchange, where he worked as a trader. It was here that he first showcased his ability to thrive in dynamic, fast-paced industries. This experience laid the groundwork for his entrepreneurial ambitions, culminating in the creation of Kokomo Capital, a high-frequency trading firm with offices spanning Sydney, Hong Kong, and New York.

Kokomo Capital became a testament to Diederik’s leadership capabilities, growing into a powerhouse firm with a diverse team of 85 professionals, half of whom were PhD-level experts. By fostering collaboration and embracing innovation, Diederik drove the company to achieve significant financial success, with revenues reaching eight figures at its peak. This experience not only honed his business acumen but also instilled in him a profound respect for the power of collaboration and the impact of collective expertise.

Transitioning to Biotech and Healthcare

After a successful exit from Kokomo Capital, Diederik shifted his focus to portfolio investments, particularly in technology and biotech. His interest in transformative ventures led him to found NKore Biotherapeutics in 2019, a groundbreaking company in the field of immunotherapy. NKore, spun out of UCLA, specializes in natural killer (NK) cell therapies, which have demonstrated exceptional promise in combating life-threatening diseases such as cancer.

As a co-founder and board member of NKore, Diederik played a pivotal role in guiding the company’s growth. Under his leadership, the company launched international clinical trials and began laying the groundwork for FDA approval in the U.S. His involvement in NKore marked the beginning of a deeper commitment to harnessing science and technology to create impactful healthcare solutions.

Celljevity: A Visionary Approach to Regenerative Medicine

Building on the success of NKore, Diederik established Celljevity to tackle some of the most pressing challenges in healthcare. The company is built on the belief that true innovation in medicine lies in addressing the root causes of disease rather than merely managing symptoms. Inspired by a blend of ancient holistic wisdom and cutting-edge science, Celljevity has developed a proprietary fibroblast rejuvenation technology that resets cells to a youthful, healthy state without altering their DNA.

Diederik’s collaboration with Dr. Yi Eve Sun, a world-renowned expert in stem cell research and epigenetics, has been instrumental in shaping Celljevity’s groundbreaking therapies. Together, they introduced Prometheus Cells, a treatment that leverages epigenetic reprogramming to rejuvenate patients’ cells, addressing degenerative conditions at their source. This technology has shown remarkable efficacy, with over 1,000 successful patient treatments to date.

For Diederik, Celljevity represents more than just scientific progress—it embodies his personal mission to redefine healthcare by making innovative treatments accessible to all. His approach emphasizes inclusivity, ensuring that these life-changing therapies are not limited to the affluent but are available to underserved populations worldwide.

A Leader with a Vision for Healthcare’s Future

As the CEO and Chairman of Celljevity, Diederik van der Reijt is leading the charge in transforming regenerative medicine. His leadership style combines strategic foresight with operational precision, ensuring that Celljevity not only pioneers groundbreaking therapies but also delivers them to patients in a scalable and impactful manner. For Diederik, the ultimate measure of success is the ability to democratize access to life-changing medical innovations.

Under his guidance, Celljevity is actively working toward listing on the NASDAQ. This move, according to Diederik, is about more than securing capital; it is about amplifying the company’s mission and opening doors for greater global collaboration. As both CEO and Chairman, Diederik remains committed to driving Celljevity’s growth and ensuring its long-term success. His dual role reflects his dedication to steering the company through this pivotal phase while staying deeply involved in both strategic and operational leadership. This steadfast commitment underscores his belief in resilient, mission-driven organizations capable of shaping the future of healthcare.

Scientific Innovations That Redefine Possibilities

Celljevity’s work is rooted in technological and scientific breakthroughs that address the underlying causes of disease. At the core of its innovation is a proprietary fibroblast rejuvenation process that reprograms a patient’s cells to a youthful state using epigenetic techniques. Unlike traditional gene-editing approaches, this process does not alter the DNA, ensuring safety while delivering transformative results.

Central to this innovation is the concept of telomere extension. Telomeres, the protective caps at the ends of chromosomes, shorten as we age, contributing to cellular degradation. Celljevity’s treatments lengthen these telomeres, effectively reversing biological aging and restoring the body’s natural regenerative capabilities. With over 1,000 patients already experiencing the benefits of this therapy, the results are compelling—ranging from improved quality of life to significant progress in managing conditions like ALS, autoimmune diseases, and degenerative joint disorders.

Diederik’s partnership with Dr. Yi Eve Sun has been pivotal in bringing these technologies to life. Their collaborative approach integrates insights from Eastern holistic practices with Western scientific rigor, creating therapies that are both innovative and accessible. This blend of expertise and vision has positioned Celljevity at the forefront of a new era in regenerative medicine.

Personal Connections and Motivations

Diederik’s passion for healthcare innovation is deeply personal. Over the years, he has witnessed the profound impact that access to effective treatments—or the lack thereof—can have on individuals and families. His experiences with friends and colleagues facing critical health challenges have instilled in him a drive to ensure that life-saving therapies are accessible to all, regardless of their socioeconomic status.

One story that resonates deeply with Diederik is that of a former colleague who faced a life-threatening melanoma diagnosis. With financial support from Diederik and his brother, the individual was able to access experimental treatment, ultimately saving their life. Conversely, Diederik recalls the heartbreak of losing a childhood friend to stage 4 lung cancer, despite best efforts to find an effective therapy. These contrasting experiences have shaped his mission at Celljevity, driving his commitment to creating therapies that are both effective and inclusive.

Diederik’s approach to healthcare reflects his belief in a paradigm shift—from reactive treatment of symptoms to proactive restoration of the body’s natural healing abilities. This philosophy guides every aspect of Celljevity’s work, from its technological innovations to its emphasis on making treatments accessible worldwide.

Shaping the Future of Medicine

Celljevity’s potential extends beyond its current breakthroughs. Diederik envisions a future where regenerative medicine is not just a luxury for the wealthy but a universal standard of care. To achieve this, he has prioritized scalability and inclusivity in the company’s operations. For instance, Celljevity has committed to making its intellectual property freely available to less-developed regions, ensuring that its therapies benefit humanity as a whole.

The company’s clinical trials, conducted in innovative settings such as Kazakhstan, reflect this focus on efficiency and accessibility. By leveraging cost-effective and streamlined healthcare systems, Celljevity is able to validate its treatments quickly while maintaining rigorous scientific standards. These efforts align with Diederik’s broader goal of bridging the gap between cutting-edge science and real-world application.

As Diederik leads Celljevity into its next phase, he remains focused on its overarching mission: to redefine healthcare by addressing root causes of disease, extending health span, and empowering the body’s natural ability to heal. Through his leadership, Celljevity is poised to not only revolutionize regenerative medicine but also set a new benchmark for what it means to deliver impactful, accessible healthcare.